Application of pseudotyped virus particles to monitor Ebola virus and SARS-CoV-2 viral entry in human cell lines

Experimental work on highly pathogenic viruses such as Ebola virus (EBOV) and severe acute respiratory syndrome coronavirus-2 requires high-level biosafety facilities. Here, we provide a detailed step-by-step protocol which details the production and application of replication-incompetent murine leu...

Descripción completa

Detalles Bibliográficos
Autores principales: Eichler, Madeleine, Aksi, Ebru, Pfeilschifter, Josef, Imre, Gergely
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390363/
https://www.ncbi.nlm.nih.gov/pubmed/34467222
http://dx.doi.org/10.1016/j.xpro.2021.100818
_version_ 1783743072699416576
author Eichler, Madeleine
Aksi, Ebru
Pfeilschifter, Josef
Imre, Gergely
author_facet Eichler, Madeleine
Aksi, Ebru
Pfeilschifter, Josef
Imre, Gergely
author_sort Eichler, Madeleine
collection PubMed
description Experimental work on highly pathogenic viruses such as Ebola virus (EBOV) and severe acute respiratory syndrome coronavirus-2 requires high-level biosafety facilities. Here, we provide a detailed step-by-step protocol which details the production and application of replication-incompetent murine leukemia virus-based pseudotyped particles to monitor and quantify the viral entry efficiency in human cell lines under biosafety level-2 conditions. We describe the use of viral particles encoding luciferase gene and the quantification of transduction efficiency by measuring luciferase activity. For complete details on the use and execution of this protocol, please refer to Imre et al. (2021).
format Online
Article
Text
id pubmed-8390363
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83903632021-08-27 Application of pseudotyped virus particles to monitor Ebola virus and SARS-CoV-2 viral entry in human cell lines Eichler, Madeleine Aksi, Ebru Pfeilschifter, Josef Imre, Gergely STAR Protoc Protocol Experimental work on highly pathogenic viruses such as Ebola virus (EBOV) and severe acute respiratory syndrome coronavirus-2 requires high-level biosafety facilities. Here, we provide a detailed step-by-step protocol which details the production and application of replication-incompetent murine leukemia virus-based pseudotyped particles to monitor and quantify the viral entry efficiency in human cell lines under biosafety level-2 conditions. We describe the use of viral particles encoding luciferase gene and the quantification of transduction efficiency by measuring luciferase activity. For complete details on the use and execution of this protocol, please refer to Imre et al. (2021). Elsevier 2021-08-27 /pmc/articles/PMC8390363/ /pubmed/34467222 http://dx.doi.org/10.1016/j.xpro.2021.100818 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Protocol
Eichler, Madeleine
Aksi, Ebru
Pfeilschifter, Josef
Imre, Gergely
Application of pseudotyped virus particles to monitor Ebola virus and SARS-CoV-2 viral entry in human cell lines
title Application of pseudotyped virus particles to monitor Ebola virus and SARS-CoV-2 viral entry in human cell lines
title_full Application of pseudotyped virus particles to monitor Ebola virus and SARS-CoV-2 viral entry in human cell lines
title_fullStr Application of pseudotyped virus particles to monitor Ebola virus and SARS-CoV-2 viral entry in human cell lines
title_full_unstemmed Application of pseudotyped virus particles to monitor Ebola virus and SARS-CoV-2 viral entry in human cell lines
title_short Application of pseudotyped virus particles to monitor Ebola virus and SARS-CoV-2 viral entry in human cell lines
title_sort application of pseudotyped virus particles to monitor ebola virus and sars-cov-2 viral entry in human cell lines
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390363/
https://www.ncbi.nlm.nih.gov/pubmed/34467222
http://dx.doi.org/10.1016/j.xpro.2021.100818
work_keys_str_mv AT eichlermadeleine applicationofpseudotypedvirusparticlestomonitorebolavirusandsarscov2viralentryinhumancelllines
AT aksiebru applicationofpseudotypedvirusparticlestomonitorebolavirusandsarscov2viralentryinhumancelllines
AT pfeilschifterjosef applicationofpseudotypedvirusparticlestomonitorebolavirusandsarscov2viralentryinhumancelllines
AT imregergely applicationofpseudotypedvirusparticlestomonitorebolavirusandsarscov2viralentryinhumancelllines

Ejemplares similares